• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Biotech’s newborn unicorn Sana grabs Harvard tech aimed at slipping engineered stem cells...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Mar 26, 2019 at 11:22: PM
via After leading one of the early pioneers in customized cancer therapies using patient cells for CAR-T, the founding execs at Sana Biotechnology are now nailing down the IP for a new generation of off-the-shelf cell therapies that they believe can have built-in protection against an immune response.

article source
 




Top Bottom
Back
Quote